789 related articles for article (PubMed ID: 34445415)
21. The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing.
Qian L; Li D; Ma L; He T; Qi F; Shen J; Lu XA
Cell Immunol; 2016; 304-305():49-54. PubMed ID: 26996927
[TBL] [Abstract][Full Text] [Related]
22. Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma.
Köksal H; Dillard P; Josefsson SE; Maggadottir SM; Pollmann S; Fåne A; Blaker YN; Beiske K; Huse K; Kolstad A; Holte H; Kvalheim G; Smeland EB; Myklebust JH; Inderberg EM; Wälchli S
Blood Adv; 2019 Apr; 3(8):1230-1243. PubMed ID: 30979721
[TBL] [Abstract][Full Text] [Related]
23. Point mutation in
Zhang Z; Chen X; Tian Y; Li F; Zhao X; Liu J; Yao C; Zhang Y
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33023981
[TBL] [Abstract][Full Text] [Related]
24. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19
Liu Q; Xu Y; Mou J; Tang K; Fu X; Li Y; Xing Y; Rao Q; Xing H; Tian Z; Wang M; Wang J
Cytotherapy; 2020 Oct; 22(10):552-562. PubMed ID: 32747298
[TBL] [Abstract][Full Text] [Related]
25. CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma.
Schomer NT; Jiang ZK; Lloyd MI; Klingemann H; Boissel L
Cytotherapy; 2022 Aug; 24(8):827-834. PubMed ID: 35400595
[TBL] [Abstract][Full Text] [Related]
26. Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival.
Julamanee J; Terakura S; Umemura K; Adachi Y; Miyao K; Okuno S; Takagi E; Sakai T; Koyama D; Goto T; Hanajiri R; Hudecek M; Steinberger P; Leitner J; Nishida T; Murata M; Kiyoi H
Mol Ther; 2021 Sep; 29(9):2677-2690. PubMed ID: 33940156
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
28. Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha.
Young PA; Yamada RE; Trinh KR; Vasuthasawat A; De Oliveira S; Yamada DH; Morrison SL; Timmerman JM
J Interferon Cytokine Res; 2018 Jun; 38(6):239-254. PubMed ID: 29920129
[TBL] [Abstract][Full Text] [Related]
29. CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD.
Imura Y; Ando M; Kondo T; Ito M; Yoshimura A
JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32525846
[TBL] [Abstract][Full Text] [Related]
30. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.
Yan ZX; Li L; Wang W; OuYang BS; Cheng S; Wang L; Wu W; Xu PP; Muftuoglu M; Hao M; Yang S; Zhang MC; Zheng Z; Li J; Zhao WL
Clin Cancer Res; 2019 Dec; 25(23):6995-7003. PubMed ID: 31444250
[TBL] [Abstract][Full Text] [Related]
31. Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CAR T-cells via TGF-β signaling.
Hao Y; Chen P; Guo S; Li M; Jin X; Zhang M; Deng W; Li P; Lei W; Liang A; Qian W
Front Med; 2024 Feb; 18(1):128-146. PubMed ID: 37870681
[TBL] [Abstract][Full Text] [Related]
32. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
33. T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells.
Mihara K; Yoshida T; Takei Y; Sasaki N; Takihara Y; Kuroda J; Ichinohe T
J Hematol Oncol; 2017 Jun; 10(1):116. PubMed ID: 28595585
[TBL] [Abstract][Full Text] [Related]
34. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
Kochenderfer JN; Rosenberg SA
Nat Rev Clin Oncol; 2013 May; 10(5):267-76. PubMed ID: 23546520
[TBL] [Abstract][Full Text] [Related]
35. CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models.
Tsukahara T; Ohmine K; Yamamoto C; Uchibori R; Ido H; Teruya T; Urabe M; Mizukami H; Kume A; Nakamura M; Mineno J; Takesako K; Riviere I; Sadelain M; Brentjens R; Ozawa K
Biochem Biophys Res Commun; 2013 Aug; 438(1):84-9. PubMed ID: 23872144
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Nonviral
Lin Z; Liu X; Liu T; Gao H; Wang S; Zhu X; Rong L; Cheng J; Cai Z; Xu F; Tan X; Lv L; Li Z; Sun Y; Qian Q
Front Immunol; 2021; 12():802705. PubMed ID: 35082789
[TBL] [Abstract][Full Text] [Related]
37. Versatile strategy for controlling the specificity and activity of engineered T cells.
Ma JS; Kim JY; Kazane SA; Choi SH; Yun HY; Kim MS; Rodgers DT; Pugh HM; Singer O; Sun SB; Fonslow BR; Kochenderfer JN; Wright TM; Schultz PG; Young TS; Kim CH; Cao Y
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E450-8. PubMed ID: 26759368
[TBL] [Abstract][Full Text] [Related]
38. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
39. Human T Cells Expressing a CD19 CAR-T Receptor Provide Insights into Mechanisms of Human CD19-Positive β Cell Destruction.
Ma H; Jeppesen JF; Jaenisch R
Cell Rep Med; 2020 Sep; 1(6):100097. PubMed ID: 33205073
[TBL] [Abstract][Full Text] [Related]
40. CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study.
Wei G; Zhang Y; Zhao H; Wang Y; Liu Y; Liang B; Wang X; Xu H; Cui J; Wu W; Zhao K; Nagler A; Chang AH; Hu Y; Huang H
Cancer Immunol Res; 2021 Sep; 9(9):1061-1070. PubMed ID: 34290048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]